Paladin Labs Inc.
Division of Endo International PLC
www.paladin-labs.com
Latest From Paladin Labs Inc.
Deals Shaping The Medical Industry, July 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
ApoE Mounts A Comeback In Alzheimer’s
New research has identified ApoE as a potential direct regulator of transcription, suggesting a broad role for the molecule in the study of Alzheimer’s disease that could explain why the usual strategies of trying to break up accumulations of amyloid beta or regulate tau hyperphosphorylation have failed to adequately treat symptoms or cure the disease.
Telesta's Bladder Cancer Therapy To Face Questions On Evidence Adequacy
Canadian firm will try to persuade two FDA advisory committees that 129-patient, single-arm, Phase III study supports approval of MCNA for non-muscle invasive bladder cancer.
Valeant Backs Strategy With Solid Deal Record
Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.
Company Information
- Industry
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- GeriatRx
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
Canada
-
Canada
-
North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
-
Livio DiFrancesco, VP, General Mgr.
Isabelle Trempe, VP, Bus. Dev. - Contact Info
-
Paladin Labs Inc.
Phone: (514) 340-1112
100 Alexis Nihon
Ste. 600
St. Laurent, H4M 2P2
Canada